Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 3Completed 2Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 1

Interventions

Paclitaxel 5Gemcitabine 3Nivolumab 2Injections 2E 7107 2Docetaxel 2Carboplatin 2Antibodies, Monoclonal 2130-nm albumin-bound paclitaxel 2venetoclax 1trastuzumab biosimilar HLX02 1taxane 1spartalizumab 1resiniferatoxin 1poly(I).poly(c12,U) 1pegamotecan 1palbociclib 1lenvatinib 1imisopasem manganese 1icotinib 1gusacitinib 1famitinib 1eniluracil 1dabrafenib 1cyclo-tetrakis(bis(1-phenyl-3-methyl-4-benzoylpyrazolon-5-ato)mu-oxotitanium(IV)) 1cobimetinib 1brincidofovir 1ammonium trichloro(dioxoethylene-O,O'-)tellurate 1aldesleukin 1abivertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × INDUSTRY × TPI-287 × Clear all
NCT01933815 2023-02-22

Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma

Cortice Biosciences, Inc.

Phase 1/2 Suspended
92 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡